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This year’s Lasker-Koshland Special Achievement Award in Medical Science is conferred on Sir
David Weatherall for his 50 years of dedication to biomedical research, his groundbreaking discov-
eries about genetic blood diseases, and his life-long passion for bringing improved medical care to
the developing world.Sir David J. Weatherall is surely in the
center of the front row of the first-ranked
hematologists in the world. His impact
on medical genetics is second to none.
It is no surprise that he has received the
2010 Lasker-Koshland Special Achieve-Sir David J. Weatherall
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He adds this considerable honor
to a long list of distinguished career
awards, medals, and honorary
degrees from an international host of
universities, learned societies, and
most particularly, in the view of frus-
trated anglophiles who fruitlessly
yearn for royal recognition, the British
Crown itself.
Weatherall was born, raised, and
educated in Liverpool, that port city
where the Mersey River meets the
Irish Sea. At its peak, 40% of Eng-
land’s trade, huge numbers of immi-
grants, and many British subjects
migrating to the west and the east
passed through Liverpool. Weatherall
comes from a long line of ‘‘Liverpudli-
ans.’’ As a youngster, he became
infused by interests in science and
music and by that city’s first love,
football. His father was a laboratory
technician who went to college at
night and rose to become the chief
of the analytical chemistry laboratory
in a large Liverpool company as well
as a council member of the RoyalSociety of Chemistry, but his first love
was music. He was the organist and choir
master of St. Nicholas Church on the Liv-
erpool waterfront. Weatherall’s mother
was also devoted to music and was
blessed with a beautiful contralto voice.Hence the strains of Bach in the back-
ground of so many calls to the Weatherall
home in Oxford.
David Weatherall wanted to be a physi-
cian for as long as he can remember.
Whether Liverpool’s distinguished historyof tropical medicine, orthopedics, and
anesthesia was of any influence is
unknown. Whatever the reason, he
became the first in his family to go to
college and medical school: the results
of that decision proved fortunate. EvenCell 1more salutary was the national require-
ment for military service once he had
graduated with an MB (Bachelor of Medi-
cine) in 1956. Assigned to the British Army
as a medical officer, he was posted to
Singapore and then to Malaya, where in43, O1960 he reported his first cases of
the blood disease thalassemia, an
inherited hemoglobin disorder that
provides a measure of protection
against malaria. His interest in con-
genital disorders of the red cell,
particularly thalassemia, and their
interactions with malaria has never
left him. Fascinated by the role of
gene mutations in human disease
and immediately after he completed
his military commitment, he joined
the genetics-oriented Johns Hopkins
hematology training program. The
program at that time was led clinically
by the late C. Lockard Conley, and
Weatherall was inspired to pursue
genetics by the broad influence of
the late Victor McCusick.
From the very beginning of his
training, Weatherall demonstrated an
uncanny capacity to associate with
excellent scientists. He worked with
the late Ned Boyer on hemoglobin
genetics and collaborated with the
late Corrado Baglioni, then at the
Massachusetts Institute of Tech-
nology, on hemoglobin fingerprintingto prove that the alpha chains of fetal
and adult hemoglobin are derived from
the same genetic loci (Weatherall and
Baglioni, 1962). Weatherall and Baglioni
then added further evidence that the
fetal-to-adult hemoglobin switch involvesctober 1, 2010 ª2010 Elsevier Inc. 17
a change in the expression of non-alpha
chains during development.
During his training program at Johns
Hopkins, Weatherall plunged into the
details of thalassemia. The mysterious
disease had been greatly clarified by the
classic 1959 review article by Ingram
and Stretton, who correctly predicted
the occurrence of both alpha and beta
thalassemia and proposed that point
mutations in the beta globin gene might
be responsible for reduced synthesis of
beta globin. But there were many unan-
swered questions, and Weatherall was
determined to master the literature and
combine it with his own experience.
In 1965, as the sole author, he published
the first edition of The Thalassaemia
Syndromes, a uniquely valuable reference
text and critical appraisal of the field.
In the subsequent three editions, he was
joined first by his long-time colleague
John Clegg and subsequently by several
coeditors. The last edition of this monu-
mental contribution to hematology and
clinical genetics was published in 2001.
The four editions are heavily cited land-
marks in medical education and are
magnificent examples of interweaving of
literature with personal experience. They
reveal Weatherall’s understanding of
Darwin’s precept that disorders due to
gene mutations are heavily modified by
environmental circumstances. Finally,
they established Weatherall as one of
the founders of molecular medicine and
attracted many basic scientists into the
field. As a result, thalassemia led the
way toward the clinical applications of
molecular biology.
In addition to his scientific training,
Weatherall had two very important
encounters in Baltimore that were to be
extremely influential in his personal and
professional life. In 1960, he met Stella
Mayorga-Nestler in the Johns Hopkins
biochemistry department of the then
School of Hygiene, where she was work-
ing with Roger Herriott of DNA transfor-
mation fame. They were married in
Stella’s California home in 1962. A second
critically important set of encounters
included Mike Naughton, an excellent
protein chemist who was working in
the Howard Dintzis laboratory at Johns
Hopkins, and John Clegg, who had joined
Naughton after a brief (and stormy)
sojourn in Hans Neurath’s laboratory in18 Cell 143, October 1, 2010 ª2010 ElsevierSeattle. Weatherall asked the two protein
chemists for help with a critical question
on which he had been working without
great success for months. Can the ex-
pected depression of beta globin chain
synthesis be reliably detected biosynthet-
ically in the reticulocytes of patients
with beta thalassemia? Clegg suggested
that a carboxymethylcellulose column
and a buffer containing 8 molar urea
and 6-mercaptoethanol might keep the
alpha, gamma, and beta globin chains
separated, prevent their aggregation,
permit their independent isolation, and,
hence, allow the determination of their
specific activities after incubation of
blood from thalassemia patients with a
3H- or 14C-labeled amino acid (Weatherall
et al., 1965). Though the method was
malodorous and the fraction collector
permanently encrusted with crystals of
urea, it worked and clearly documented
that thalassemia is a disorder of unbal-
anced globin synthesis. Though almost
entirely replaced by modern DNA-based
methods, it remains a valuable if unwieldy
approach to the diagnosis of microcytic
anemias of unknown etiology. Clegg and
Weatherall have been colleagues ever
since.
Following his remarkably productive
sojourn in Baltimore, Weatherall returned
to the University of Liverpool where, with
his colleagues Clegg and Bill Wood,
a young trainee, he established a superb
clinical research program in hematology.
He rose to the rank of Professor of Hae-
matology and remained in Liverpool until
1974 when he moved, again with his two
close colleagues, to the University of
Oxford to be the Nuffield Professor and
then the Regius Professor of Medicine
andwhere he founded a research institute
now named the Weatherall Institute of
Molecular Medicine. The institute, the first
of its kind in Europe, opened in 1989 and
now has a staff of over 400. It is devoted
to biomedical research with a strong clin-
ical component. He retired from the
Oxford faculty in 2000 but remains
a distinguished participant in the institute,
now directed by his former student,
Douglas Higgs, a superb physician
scientist.
In addition to his many book chapters
and The Thalassaemia Syndromes,
Weatherall has been a coauthor of over
500 articles, most of which focus on thal-Inc.assemia, malaria, and the hemoglobinop-
athies. In the process of studying thalas-
semia, he has traveled the world many
times over and has trained a substantial
cadre of investigators who direct impor-
tant clinical and clinical research pro-
grams particularly in Southeast Asia.
Much of his most original clinical research
effort has illuminated the alpha thalas-
semia syndromes, conditions particularly
prevalent in Southeast Asia.
In 1974, when reverse transcriptase
permitted the development of isotopically
labeled cDNA probes, both Weatherall’s
group (Ottolenghi et al., 1974) and a group
assembled by Y.W. Kan (Taylor et al.,
1974) demonstrated that complete alpha
globin gene deletion plays a critical role
in the development of severe (and usually
fatal) hydrops fetalis with Bart’s hemoglo-
binemia. The two papers were published
back to back in the same issue of Nature.
Later it was shown that unusual point
mutations may also inhibit or even arrest
alpha globin gene expression. In fact,
in 1975, Weatherall and Clegg demon-
strated that a termination codon mutation
in one of the four alpha genes can lead to
an abnormally elongated alpha chain and
an unstable messenger RNA producing
alpha + thalassemia, but deletion is the
predominant genetic lesion in alpha 0
thalassemia.
The development of reasonably spe-
cific beta globin cDNA probes that
permitted interpretable Southern blots
was somewhat more difficult than that of
alpha globin cDNA probes because of
overlap of beta globin DNA sequences
with delta and gamma sequences. In
1976, a group assembled by Weatherall
and headed by Sergio Ottolenghi demon-
strated that both delta-beta thalassemia
and the form of hereditary persistence of
fetal hemoglobin (HPFH) found in Africans
are due to extensive gene deletions (Otto-
lenghi et al., 1976). The subtle but impor-
tant differences between the two that
lead to considerably higher gamma gene
expression in HPFH were detected later
by several groups. Only 2 years later
such a probe was utilized by Orkin and
his coworkers to exclude homozygous
delta-beta thalassemia in a first trimester
Turkish fetus at risk (Orkin et al., 1978).
The alpha thalassemias continued
to capture Weatherall’s interest and
attention, and when Douglas Higgs joined
his laboratory as a budding physician
scientist, that interest blossomed into
major findings. By this time, Weatherall’s
research unit had become a reference
laboratory for clinicians throughout Great
Britain, southern Europe, and Southeast
Asia. Among these referrals were three
blood samples from male patients of
northern European origin, each of whom
had both mental retardation and hemo-
globin H disease, a form of alpha thalas-
semia usually due to three alpha gene
deletions. Analysis of the alpha genes of
the patients and their parents revealed
that one parent did indeed have two alpha
gene deletions (as expected), but the
other had an entirely normal complement
of four alpha genes. The patients had only
two deletions. Clearly another mutation
must have been present to suppress the
expression of the intact alpha genes,
and that mutation was likely to cause the
mental retardation as well. That was
a puzzle to be solved considerably later
in a brilliant series of studies by Higgs
and his colleagues. These studies dem-
onstrated an X-linked helicase deficiency
in the male patients and subtelomeric
deletions on chromosome 16 in others
that were shown to be responsible for
reduced alpha globin gene expression
and were presumably responsible for the
mental retardation (Gibbons and Higgs,
2000).
The remarkable copresentation of
mental retardation and alpha thalassemia
stimulated Weatherall and Higgs to focus
on the molecular anatomy of the alpha
globin gene cluster. They provided the
first RFLP map of the cluster and showed
that it offered an excellent site for linkage
analysis (Higgs et al., 1986). Along the
way, they defined the alpha globin gene
locus control region. The experience
launched Higgs’ fine career.
Weatherall is a broadly interested
hematologist. Though he made many
important contributions to the genetic
basis of thalassemia, he never lost an
opportunity to explore its treatment and
prevention. Immediately after Propper
and his coworkers suggested that daily
continuous subcutaneous administra-
tion of deferoxamine might prolong the
lives of multiply transfused thalassemia
patients with consequent iron overload
(Propper et al., 1977), Pippard and
Weatherall showed that a 5 day overnightregimen would eliminate iron nearly as
well but be much more acceptable to
patients (Pippard et al., 1977). They were
correct, but the long gaps in which no
chelator could be present in the blood
diminished the efficacy of the treatment.
On the other hand, many more patients
could accept the regimen. It became the
standard of care until very recently when
deferisirox, an orally active chelator with
a long plasma half-life, became available.
Though Weatherall was rightly doubtful
that the globin chain synthesis system
that he had developed with Clegg and
Naughton (Weatherall et al., 1965) could
be reliably applied in prenatal diagnosis
using blood obtained from the placenta,
he changed his mind when he saw the
initial results of the efforts of Kan and Alter
and their colleagues (Kan et al., 1972). He
moved aggressively to establish a highly
successful prenatal detection system in
England that became a model of its kind
(Old et al., 1982) and then adopted more
practical molecular methods when they
became available.
As Weatherall began to pass the
torch of leadership of laboratory-based
research to Higgs, he directed his consid-
erable energy to his first interest, the
plight of poor patients in malaria zones
who endure high rates of both malarial
and nonmalarial infections and of in-
herited hemoglobinopathies. His publica-
tions in this important area are many, but
one of the most interesting is his finding
in Papua, New Guinea that a single alpha
gene deletion and particularly two such
deletions provide high protection from
both malarial and nonmalarial infections
(Allen et al., 1997). How a mild inherited
disorder of hemoglobin synthesis, limited
in its expression to the red cell and
manifested only as microcytosis (unusu-
ally small red blood cells), can influence
nonmalarial infection rates requires much
more understanding of host defense than
we have currently. In another fascinating
study, Weatherall and his colleagues
demonstrated that HbE/thalassemia, a
very common disorder in Southeast
Asia, provides very little protection from
malaria caused by the parasite Plasmo-
dium vivax. In fact vivax malaria infection
is one of the factors that increases the
severity of that particular thalassemia
syndrome (O’Donnell et al., 2009). Finally,
Weatherall’s efforts have provided stu-Cell 1dents of thalassemia with insights into
the clinical course of the disease as
patients age (O’Donnell et al., 2007). His
clinics in Sri Lanka are invaluable ‘‘class-
rooms’’ for young North American and
British students of the disease, particu-
larly for those who wish to find better
treatments, to learn quickly about its
manifestations and for those who intend
to contribute to the care of patients
desperately in need. Even more important
is Weatherall’s creation of an Asian Thal-
assaemia Network in which experts in
India and Thailand give technical assis-
tance to their colleagues in less devel-
oped countries such as Bangladesh and
Cambodia.
Meanwhile, Weatherall continues to
travel to major sites of the thalassemia
syndromes, urge world health authorities
and private foundations to pay attention
to the inherited hemoglobinopathies, tell
anyone who will listen about the impend-
ing world impact of the disorders, and
try to do his best to relieve the suffering
that these common inherited diseases
bring to those who can least afford to
deal with them. He does all this with
gem-like intelligence and indefatigable
determination, both mixed with mar-
velous humor and deep interest in what
his colleagues are doing. Indeed, life in
academic medicine is really all about
working with great colleagues. I have
been blessed with many, none more
enjoyable or admirable than Sir David
J. Weatherall.REFERENCES
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